Olaparib With Chemotherapy Does Not Elicit Improved Outcomes vs Chemotherapy Alone in BRCA Wild-Type TNBC

Olaparib on a gap schedule with chemotherapy does not improve responses vs chemotherapy alone in the neoadjuvant setting for patients with BRCA wild-type TNBC.

Related Keywords

United Kingdom ,California ,United States ,San Francisco ,Cambridge ,Cambridgeshire ,Karen Pinilla Alba ,Olaparib Lynparza ,University Of California ,Department Of Oncology ,United Kingdom Cancer Centre ,University Of Cambridge Cancer Research ,Helen Diller Family Comprehensive Cancer Center ,Trial Consortium ,Pinilla Alba ,Cambridge Cancer Research ,Additional Data ,News ,Conference ,Breast Cancer ,Aacr Annual Meeting ,